EP1024792A1 - Topical antifungal composition - Google Patents
Topical antifungal compositionInfo
- Publication number
- EP1024792A1 EP1024792A1 EP98951104A EP98951104A EP1024792A1 EP 1024792 A1 EP1024792 A1 EP 1024792A1 EP 98951104 A EP98951104 A EP 98951104A EP 98951104 A EP98951104 A EP 98951104A EP 1024792 A1 EP1024792 A1 EP 1024792A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- skin
- mousse
- antifungal agent
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000699 topical effect Effects 0.000 title claims abstract description 17
- 239000012871 anti-fungal composition Substances 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 105
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 30
- 239000003429 antifungal agent Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000000717 retained effect Effects 0.000 claims abstract description 13
- 208000001840 Dandruff Diseases 0.000 claims abstract description 10
- 208000002474 Tinea Diseases 0.000 claims abstract description 8
- 241000130764 Tinea Species 0.000 claims abstract description 8
- 201000010618 Tinea cruris Diseases 0.000 claims abstract description 8
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 7
- 230000002035 prolonged effect Effects 0.000 claims abstract description 6
- 208000031888 Mycoses Diseases 0.000 claims abstract description 5
- 241000195940 Bryophyta Species 0.000 claims description 59
- 235000011929 mousse Nutrition 0.000 claims description 59
- 210000003491 skin Anatomy 0.000 claims description 56
- 229960004125 ketoconazole Drugs 0.000 claims description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 210000002615 epidermis Anatomy 0.000 claims description 26
- 230000035515 penetration Effects 0.000 claims description 22
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 16
- 229960003993 chlorphenesin Drugs 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000004215 Carbon black (E152) Substances 0.000 claims description 14
- 229930195733 hydrocarbon Natural products 0.000 claims description 14
- 150000002430 hydrocarbons Chemical class 0.000 claims description 14
- 239000003380 propellant Substances 0.000 claims description 14
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 9
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 9
- 230000002459 sustained effect Effects 0.000 claims description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 6
- 230000000843 anti-fungal effect Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- -1 imidazole compound Chemical class 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 4
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 4
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 4
- 229960002867 griseofulvin Drugs 0.000 claims description 4
- 150000002460 imidazoles Chemical class 0.000 claims description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims description 3
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 3
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 229960003204 amorolfine Drugs 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 229960004365 benzoic acid Drugs 0.000 claims description 3
- 229960003749 ciclopirox Drugs 0.000 claims description 3
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 150000002009 diols Chemical class 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 229960004884 fluconazole Drugs 0.000 claims description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 3
- 229960004413 flucytosine Drugs 0.000 claims description 3
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 3
- 229960001906 haloprogin Drugs 0.000 claims description 3
- 229960004313 naftifine Drugs 0.000 claims description 3
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 claims description 3
- 229960000988 nystatin Drugs 0.000 claims description 3
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 3
- 229960002446 octanoic acid Drugs 0.000 claims description 3
- 229950004864 olamine Drugs 0.000 claims description 3
- 150000004291 polyenes Chemical class 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 claims description 3
- 229960002722 terbinafine Drugs 0.000 claims description 3
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 3
- 229960004880 tolnaftate Drugs 0.000 claims description 3
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 3
- 229930183010 Amphotericin Natural products 0.000 claims 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims 2
- 229940009444 amphotericin Drugs 0.000 claims 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 1
- XMAYWYJOQHXEEK-ZEQKJWHPSA-N (2S,4R)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@H]1O[C@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-ZEQKJWHPSA-N 0.000 description 53
- 239000002453 shampoo Substances 0.000 description 32
- 238000009472 formulation Methods 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 230000014759 maintenance of location Effects 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 12
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 238000010268 HPLC based assay Methods 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 229960000541 cetyl alcohol Drugs 0.000 description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 6
- 229940064438 nizoral Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 208000006440 Open Bite Diseases 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229940032043 quaternium-52 Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- GUIWIPNQQLZJIE-UHFFFAOYSA-K tris[2-(2-hydroxyethoxy)ethyl]-octadecylazanium;phosphate Chemical compound [O-]P([O-])([O-])=O.CCCCCCCCCCCCCCCCCC[N+](CCOCCO)(CCOCCO)CCOCCO GUIWIPNQQLZJIE-UHFFFAOYSA-K 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 230000001955 cumulated effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 239000004341 Octafluorocyclobutane Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical class CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229940057971 butane Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940056318 ceteth-20 Drugs 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- GUIWIPNQQLZJIE-UHFFFAOYSA-M dihydrogen phosphate;tris[2-(2-hydroxyethoxy)ethyl]-octadecylazanium Chemical compound OP(O)([O-])=O.CCCCCCCCCCCCCCCCCC[N+](CCOCCO)(CCOCCO)CCOCCO GUIWIPNQQLZJIE-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 150000002398 hexadecan-1-ols Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019407 octafluorocyclobutane Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
Definitions
- the present invention relates to a foamable antifungal composition for the treatment of various skin conditions.
- Antifungal agents are well known, and include macrolide antibiotics such as griseofulvin, and imidazoles such as clotrimazole and ketoconazole.
- Ketoconazole was originally described by Heeres et al in US patent 4,335,125, in which its principal utility was an antifungal compound useful in the treatment of a variety of conditions including sebborheic dermatitis, dandruff, "jock itch" and tinea.
- Antifungal compositions are traditionally applied as lotions or creams. There are however disadvantages to these forms. In particular, the formulations are frequently very viscous requiring substantial rubbing to achieve penetration into the effected area, an act in itself which causes discomfort and sometimes irritation. If the viscous formulations are not vigorously applied, the active antifungal agent does not necessarily reach the site requiring treatment being the epidermis of the skin. Non-viscous creams and lotions are wont to flow off the effected site before penetration is achieved.
- One final disadvantage is that cream and lotion bases in themselves can add to site irritation depending on their content.
- Ketoconazole was disclosed in US patent 4,569,935 to be useful in the topical treatment of psoriasis and seborrheic dermatitis. Pursuant to this utility, ketoconazole has been marketed in a 2% shampoo formulation for the treatment of scaling due to dandruff, sold under the brand name "Nizoral®". This shampoo is applied by the user and then removed shortly, for example 3-5 minutes, after its application by rinsing with water. The active agent is thus only in contact with the area to be treated for a very limited time.
- ketoconazole based shampoos are US5,456,851 in the name of JOHNSON & JOHNSON CONSUMER PRODUCTS, INC which aims to provide good cosmetic properties to the shampoo including lather, and to retard degradation of the ketoconazole.
- This composition is a foaming formulation.
- the disadvantage of such shampoo formulations is that during normal usage, the formulation does not remain on the scalp for a period of time sufficient to allow the antifungal agent to achieve its maximal therapeutic effect since they are designed to be applied, for example in the shower or bath, and shortly after rinsed off with water. Typically, the application instructions for such shampoos suggest that the formulation be removed after 3-5 minutes.
- AU 80257/87 In order to achieve maximal therapeutic effect, one alternative such as is described in AU 80257/87, is to provide a high quantity of residual solids which remain after application to treat the offending skin condition.
- a foam composition for the delivery of minoxidil There is disclosed in AU 80257/87 a foam composition for the delivery of minoxidil.
- the formulations disclosed in this document all contain a high percentage of nonvolatile residues, including propylene giycol. While it is not disclosed why these formulations contain such a large amount of propylene giycol, it is postulated that the propylene giycol is probably required either to enhance the penetration and/or to improve the solubility of the minoxidil.
- the disadvantage of a composition with a high residual content is that the non-volatile residues are retained at the site of application and therefore feel unpleasant and unattractive to the user.
- ketoconazole and minoxidil are decribed in AU-A- 35717/93 in the name of SMITH KLINE BEECHAM PLC which discloses compositions including a novel androstene steroid for use in the treatment of acne and sebborrhea, and AU-A-48851/96 in the name of MEDEVA PLC which describes the use of betamethasone in a quick breaking foam including a buffering agent for use in the treatment of skin diseases and particularly scalp psoriasis.
- a topical, foamable composition including at least one antifungal agent, said composition characterised in that said at least one antifungal agent is able to penetrate the upper layers of the skin and is retained in or on an area to be treated for a prolonged period of time, and in that it has a residual non-volatile component content of less that 25%.
- the antifungal composition of the present invention has a commercially acceptable cosmetic appeal and during normal usage allows greater penetration and retention of the antifungal agent in the upper layers of the skin, particularly in the epidermis, thus providing a reservoir of active agent available to achieve a sustained antifungal effect when compared against known formulations.
- This latter feature leads to enhanced pharmaceutical appeal as well as cosmetic appeal.
- the residual solids content of the formulation is so low as to not provide discomfort and irritation to the user
- Prolonged period of time is meant to encompass periods of time sufficiently long so as to enable the active agent present to be substantially fully absorbed by the organism being treated, or substantially fully metabolised by the patient being treated.
- the one or more antifungal agents is selected from the group consisting of diols, allylamines (including naftifine and terbinafine), polyene macrolide antibiotics (including amphote cin and nystatin), triazole derivatives (such as fluconazole), fatty acids (such as caprylic and propionic acid), amorolfine, ciclopirox, olamine, benzoic acid, flucytosine, haloprogin, tolnaftate, undecenoic acid and its salts, griseofulvin and imidazole compounds. More preferably, the antifungal is an imidazole compound. Most preferably, the antifungal agent is ketoconazole or chlorphenesin (3-(4-Chlorphenoxy)propane-1 ,2-diol).
- compositions according to the invention have a residual non-volatile component content of less that 10%, and more preferably of less than 6%.
- topical, foamable composition is provided as a mousse.
- the mousse is a temperature sensitive mousse, which breaks down rapidly when exposed to the skin temperature.
- the composition is an ethanolic mousse including a lower alcohol content of greater than 10%, more preferably greater than 50% and a hydrocarbon gas content propellent of less than 60%, more preferably less than 10%.
- the composition is an aqueous mousse including no lower alcohol content and a hydrocarbon gas content propellent of less than 60%, more preferably less than 10%.
- the long chain alcohol may be chosen from, for example, cetyl, stearyl, lauryl, myristyl and palmityl alcohols and mixtures of two or more thereof.
- the lower alcohol may preferably be chosen from methyl, ethyl, isopropyl and butyl alcohols, and mixtures of two or more thereof. Ethanol has been found to be particularly preferred.
- Surfactants utilised in the temperature sensitive mousse may preferably be chosen from ethoxylated sorbitan stearate, palmitate, oleate, nonyl phenol ethoxylates and fatty alcohol ethoxylates, and mixtures of two or more thereof.
- Polysorbate 60 (a mixture of partial stearic esters of sorbitol and its anhydrides copolymerised with approximately 20 moles of ethylene oxide for each mole of sorbitol and its anhydrides) has been found to be particularly preferred.
- the surfactant enhances the long chain alcohol solubility in the system and enhances mousse formation.
- a foamable composition including up to 5% of long chain alcohols up to 5% of quaternary compound up to 10% of propylene giycol up to 5% of antifungal agent up to 90% of lower alcohol solvent up to 5% of surfactant
- the long chain alcohol is cetyl or stearyl alcohol or mixtures thereof.
- the quaternary compound is quaternium oxy ethyl alkyl ammonium phosphate commercially available under the trade name, Dehyquart SP.
- the lower alcohol solvent is ethanol or propanol or mixtures thereof.
- Suitable gas propellants include non-toxic gas propellants suited to foamable cosmetic and pharmaceutical compositions and known to those skilled in the art.
- propellant from propane, butane, dichloro difluoro methane, dichloro tetrafluoro ethane, octafluoro cyclobutane, and mixtures of two or more thereof. It is necessary to select a propellant most compatible with the entire system. The maximum level of propellant will be determined as the amount miscible with the utilized water/lower alcohol ratio. In addition to acting as a propellant, the propellant will also act as a solvent for the long chain alcohol and active substances in the aqueous/alcoholic system.
- compositions for the treatment of fungal skin conditions including dandruff, seborrheic dermatitis, tinea, jock itch and the like, said composition characterised in that it is a foamable mousse applicable to the skin of the user in the substantial absence of water and without substantially immediate removal by washing.
- said composition has a non-volatile component content of less than 25%, preferably less than 10% and more preferably less than 6%.
- the mousse is a temperature sensitive mousse, which breaks down rapidly when exposed to the skin temperature.
- the composition is a mousse including a lower alcohol content of greater than 10%, more preferably greater than 50% and a hydrocarbon gas content propellent of less than 60%, more preferably less than 10%.
- a topical, foamable composition including an antifungal agent characterised in that upon application to the skin of a user a penetration of at least 10 ⁇ g/cm2 is achieved in the epidermis within one hour of application and sustained over a period of at least
- the invention provides a topical, foamable composition characterised in that upon application to the skin of a user a penetration of at least 30 ⁇ g/cm2 is achieved in the epidermis within one hour of application and sustained over a period of at least 23 hours.
- the invention provides a topical, foamable composition characterised in that upon application to the skin of a user a penetration of at least 10 ⁇ g/cm2 is achieved in the epidermis within one hour of application and sustained over a period of at least 23 hours.
- a method of treating fungal infections, particularly tinea, jock itch, dandruff and sebborheic dermatitis by applying to the affected area of a patient requiring such treatment the antifungal composition of the present invention.
- the composition is allowed to remain on the affected area for an extended period of time.
- extended period of time means a length of time greater than the length of time that prior art topical compositions such as shampoos are prescribed to remain in contact with the affected area.
- shampoos are designed to be washed off within 5 minutes. More preferably, when the composition is used to treat dandruff or sebborheic dermatitis, it is applied at one wash or between washes and is allowed to remain on the site of application such as the scalp or hair until the site of application is subsequently washed again.
- the invention also encompasses the use of an antifungal agent in the preparation of a topical foamable composition for the treatment of fungal diseases including dandruff, tinea, jock itch and sebborheic dermatitis, the topical foamable composition being characterised in that it is able to penetrate the epidermis of the skin and is retained in or on an area to be treated for a prolonged period of time, and in that it has a non-volatile component content of less that 25%.
- P75 Hydrocarbon Propellant 4.30 The compositions were prepared by dissolving the active in the ethanol. the cetyl and stearyl alcohol are then added to the heated solution and mixed until dissolved. The quaternium 52, propylene giycol and water are then added and stirred until homogenous, while maintaining the elevated temperature. The solution is then dispensed into aerosol cans where the aerosol valve is then fitted and the can charged with propellant.
- HPLC equipment Shimadzu automated HPLC system with uv detector, bovine serum albumin dissolved in phosphate buffered saline (pH 7.4) as receptor phase to mimic physiological conditions.
- Table 1 shows the cumulated ketoconazole in both the receptor phase and the epidermis at defined time points following application of the mousse according to the invention and the shampoo of the prior art.
- N not detectable (assuming to be zero for calculating mean and SD) -: not available Table 2 shows the cumulated ketoconazole in both receptor (expressed as ⁇ g/ml receptor fluid) and epidermis (expressed as ⁇ g/cm2 surface area) at defined time points following application of the mousse according to the present invention and the shampoo of the prior art.
- FIG. 1 shows the time course of the ketoconazole penetrating across human epidermis to receptor fluid.
- the closed points of the graph represent 0.5% mousse, the open points represent 1.0% mousse.
- Data are the mean ⁇ SD of triplicate (from Table 2).
- Figure 2 represents the time course of ketoconazole retained in the epidermis.
- the closed points of the graph represent 0.5% mousse, the open points represent 1.0% mousse.
- Data are the mean ⁇ SD of triplicate (from Table 2).
- Figure 3 compares the levels of retention of ketoconazole on the skin, the levels of retention of the ketoconazole in the skin and the amount of ketoconazole passed through the skin in the tests using a mousse according to the invention with the same measures using Nizoral®. Note that ketoconazole levels found after application of the Nizoral® shampoo were low and thus are not visible in this figure It can readily be observed from the results of example 1 that:
- ketoconazole in the mousse compositions of the present invention penetrated the skin in appreciable quantity
- ketoconazole in the mousse composition of the present invention was preferentially retained in the epidermis compared to penetration into the receptor solution;
- Receptor phase 4% bovine serum albumin (BSA) in phosphate buffered saline
- Amount of ketoconazole in full thickness skin and receptor phase measured by
- HPLC assay for ketoconazole content HPLC assay for ketoconazole content.
- Ketoconazole was extracted from full thickness skin sample by soaking in methanol for 1 hour. This procedure was repeated with a second volume of methanol for 30 mins. The methanol samples were combined from HPLC analysis. [This procedure has been validated with a 99% recovery rate].
- Figure 4 shows the HPLC standard curve for ketoconazole.
- Table 3 shows the amount of ketoconazole retained in the skin ( ⁇ g/cm2) at 15, 60 minutes, 12 and 24 hours following application of the mousse according to the invention, or the shampoo of the prior art.
- Ketoconazole retained in skin ( ⁇ g/cm2) at 15, 60 mins, 12, 24 hours following application of mousse or shampoo.
- Table 4 shows the amount of Ketoconazole penetrated to the receptor phase ( ⁇ g/mL) at 12, 24 hours following application of the mousse according to the invention, or the shampoo of the prior art.
- Ketoconazole penetrated to receptor phase ( ⁇ g/mL) at 12, 24 hours following application of mousse or shampoo.
- the mousse formulation according to the invention demonstrated significantly greater skin retention of ketoconazole than the shampoo formulation of the prior art over the 24 hour period.
- EXAMPLE 3 A third study was undertaken to compare the skin penetration and retention of two formulations according to the invention in which the active anti fungal agent was chlorphenesin (0.5% w/w).
- One formulation was ethanolic and had a total residue content of 2.5% solids including active, the other formulation was aqueous and had a total residue content of 4.6% solids including active.
- HPLC equipment Shimadzu automated HPLC system with uv detector.
- Receptor phase 4% bovine serum albumin (BSA) in phosphate buffered saline
- Table 5 shows the amount of chlorphenesin retained in the skin ( ⁇ g/cm2) at 15, 60 minutes, 12 and 24 hours following application of the mousse according to the invention.
- Table 6 shows the amount of chlorphenesin penetrated to the receptor phase ( ⁇ g/mL) at 12, 24 hours following application of the mousse according to 10 the invention.
- Figure 7 shows the amount of chlorphenesin retained in the skin versus the time after application of the formulation according to the invention.
- the open points are the aqueous formulation.
- the closed points represent the ethanolic formulation. 15 It is readily observed from the results of example 3 that active agents other than ketoconazole formulated as both ethanolic and aqueous compositions achieve the desired penetration and retention levels for effective treatment of fungal skin conditions. It will be appreciated that the scope of this invention goes beyond the specific formulations exemplified to encompass topical foamable antifungal compositions having like components to those specifically mentioned but having characteristic penetration and retention levels in the skin of the user, and low levels of residual solid content as defined.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a topical, foamable composition including at least one antifungal agent, said composition characterised in that said at least one antifungal agent is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and in that it has a residual non-volatile component content of less than 25 %. The invention furthermore relates to a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis by applying to the affected area of a patient requiring such treatment the antifungal composition as claimed in any one of claims 1-29.
Description
Topical Antifungal Composition
Background of the Invention
The present invention relates to a foamable antifungal composition for the treatment of various skin conditions. Antifungal agents are well known, and include macrolide antibiotics such as griseofulvin, and imidazoles such as clotrimazole and ketoconazole.
Ketoconazole was originally described by Heeres et al in US patent 4,335,125, in which its principal utility was an antifungal compound useful in the treatment of a variety of conditions including sebborheic dermatitis, dandruff, "jock itch" and tinea.
Antifungal compositions are traditionally applied as lotions or creams. There are however disadvantages to these forms. In particular, the formulations are frequently very viscous requiring substantial rubbing to achieve penetration into the effected area, an act in itself which causes discomfort and sometimes irritation. If the viscous formulations are not vigorously applied, the active antifungal agent does not necessarily reach the site requiring treatment being the epidermis of the skin. Non-viscous creams and lotions are wont to flow off the effected site before penetration is achieved. One final disadvantage is that cream and lotion bases in themselves can add to site irritation depending on their content.
Ketoconazole was disclosed in US patent 4,569,935 to be useful in the topical treatment of psoriasis and seborrheic dermatitis. Pursuant to this utility, ketoconazole has been marketed in a 2% shampoo formulation for the treatment of scaling due to dandruff, sold under the brand name "Nizoral®". This shampoo is applied by the user and then removed shortly, for example 3-5 minutes, after its application by rinsing with water. The active agent is thus only in contact with the area to be treated for a very limited time.
Another patent describing ketoconazole based shampoos is US5,456,851 in the name of JOHNSON & JOHNSON CONSUMER PRODUCTS, INC which aims to provide good cosmetic properties to the shampoo including lather, and to retard degradation of the ketoconazole. This composition is a foaming formulation.
The disadvantage of such shampoo formulations is that during normal usage, the formulation does not remain on the scalp for a period of time sufficient to allow the antifungal agent to achieve its maximal therapeutic effect since they are designed to be applied, for example in the shower or bath, and shortly after rinsed off with water. Typically, the application instructions for such shampoos suggest that the formulation be removed after 3-5 minutes.
In order to achieve maximal therapeutic effect, one alternative such as is described in AU 80257/87, is to provide a high quantity of residual solids which remain after application to treat the offending skin condition. There is disclosed in AU 80257/87 a foam composition for the delivery of minoxidil. The formulations disclosed in this document all contain a high percentage of nonvolatile residues, including propylene giycol. While it is not disclosed why these formulations contain such a large amount of propylene giycol, it is postulated that the propylene giycol is probably required either to enhance the penetration and/or to improve the solubility of the minoxidil. The disadvantage of a composition with a high residual content is that the non-volatile residues are retained at the site of application and therefore feel unpleasant and unattractive to the user.
Alternatives to ketoconazole and minoxidil are decribed in AU-A- 35717/93 in the name of SMITH KLINE BEECHAM PLC which discloses compositions including a novel androstene steroid for use in the treatment of acne and sebborrhea, and AU-A-48851/96 in the name of MEDEVA PLC which describes the use of betamethasone in a quick breaking foam including a buffering agent for use in the treatment of skin diseases and particularly scalp psoriasis.
It is an aim of this invention to provide an antifungal composition which is effective in its treatment of fungal skin conditions but which is also pleasant to use. Summary of the Invention To this end, in a first aspect of the invention, there is provided a topical, foamable composition including at least one antifungal agent, said composition characterised in that said at least one antifungal agent is able to penetrate the
upper layers of the skin and is retained in or on an area to be treated for a prolonged period of time, and in that it has a residual non-volatile component content of less that 25%.
It has been surprisingly found that the antifungal composition of the present invention has a commercially acceptable cosmetic appeal and during normal usage allows greater penetration and retention of the antifungal agent in the upper layers of the skin, particularly in the epidermis, thus providing a reservoir of active agent available to achieve a sustained antifungal effect when compared against known formulations. This latter feature leads to enhanced pharmaceutical appeal as well as cosmetic appeal. Moreover, the residual solids content of the formulation is so low as to not provide discomfort and irritation to the user
The term "prolonged period of time" is meant to encompass periods of time sufficiently long so as to enable the active agent present to be substantially fully absorbed by the organism being treated, or substantially fully metabolised by the patient being treated.
In a preferred embodiment, the one or more antifungal agents is selected from the group consisting of diols, allylamines (including naftifine and terbinafine), polyene macrolide antibiotics (including amphote cin and nystatin), triazole derivatives (such as fluconazole), fatty acids (such as caprylic and propionic acid), amorolfine, ciclopirox, olamine, benzoic acid, flucytosine, haloprogin, tolnaftate, undecenoic acid and its salts, griseofulvin and imidazole compounds. More preferably, the antifungal is an imidazole compound. Most preferably, the antifungal agent is ketoconazole or chlorphenesin (3-(4-Chlorphenoxy)propane-1 ,2-diol).
Preferably the compositions according to the invention have a residual non-volatile component content of less that 10%, and more preferably of less than 6%.
In a preferred embodiment the topical, foamable composition is provided as a mousse.
In a further preferred embodiment the mousse is a temperature sensitive mousse, which breaks down rapidly when exposed to the skin temperature.
In a still further embodiment, the composition is an ethanolic mousse including a lower alcohol content of greater than 10%, more preferably greater than 50% and a hydrocarbon gas content propellent of less than 60%, more preferably less than 10%. In an alternative embodiment the composition is an aqueous mousse including no lower alcohol content and a hydrocarbon gas content propellent of less than 60%, more preferably less than 10%.
(Unless specified otherwise in the specification, all % are based on the total weight of the composition.) In the temperature sensitive mousse, the long chain alcohol may be chosen from, for example, cetyl, stearyl, lauryl, myristyl and palmityl alcohols and mixtures of two or more thereof.
The lower alcohol may preferably be chosen from methyl, ethyl, isopropyl and butyl alcohols, and mixtures of two or more thereof. Ethanol has been found to be particularly preferred.
Surfactants utilised in the temperature sensitive mousse may preferably be chosen from ethoxylated sorbitan stearate, palmitate, oleate, nonyl phenol ethoxylates and fatty alcohol ethoxylates, and mixtures of two or more thereof.
Thus, for example, Polysorbate 60 (a mixture of partial stearic esters of sorbitol and its anhydrides copolymerised with approximately 20 moles of ethylene oxide for each mole of sorbitol and its anhydrides) has been found to be particularly preferred. The surfactant enhances the long chain alcohol solubility in the system and enhances mousse formation.
In a further aspect of the invention, there is provided a foamable composition including up to 5% of long chain alcohols up to 5% of quaternary compound up to 10% of propylene giycol up to 5% of antifungal agent up to 90% of lower alcohol solvent up to 5% of surfactant
5-95% of water, and
up to 20% of a hydrocarbon gas propellant
Preferably, the long chain alcohol is cetyl or stearyl alcohol or mixtures thereof.
Preferably, the quaternary compound is quaternium oxy ethyl alkyl ammonium phosphate commercially available under the trade name, Dehyquart SP.
Preferably, the lower alcohol solvent is ethanol or propanol or mixtures thereof.
Suitable gas propellants include non-toxic gas propellants suited to foamable cosmetic and pharmaceutical compositions and known to those skilled in the art.
Thus, one may select the propellant from propane, butane, dichloro difluoro methane, dichloro tetrafluoro ethane, octafluoro cyclobutane, and mixtures of two or more thereof. It is necessary to select a propellant most compatible with the entire system. The maximum level of propellant will be determined as the amount miscible with the utilized water/lower alcohol ratio. In addition to acting as a propellant, the propellant will also act as a solvent for the long chain alcohol and active substances in the aqueous/alcoholic system.
In a second aspect of the invention there is provided a composition for the treatment of fungal skin conditions including dandruff, seborrheic dermatitis, tinea, jock itch and the like, said composition characterised in that it is a foamable mousse applicable to the skin of the user in the substantial absence of water and without substantially immediate removal by washing.
In a preferred embodiment of this aspect of the invention, said composition has a non-volatile component content of less than 25%, preferably less than 10% and more preferably less than 6%.
In a more preferred embodiment of this aspect of the invention, the mousse is a temperature sensitive mousse, which breaks down rapidly when exposed to the skin temperature. In a still further preferred embodiment, the composition is a mousse including a lower alcohol content of greater than 10%, more preferably greater than 50% and a hydrocarbon gas content propellent of less than 60%, more
preferably less than 10%.
In a further aspect of the invention there is provided a topical, foamable composition including an antifungal agent characterised in that upon application to the skin of a user a penetration of at least 10μg/cm2 is achieved in the epidermis within one hour of application and sustained over a period of at least
23 hours.
When the preferred active agent is ketoconazole, the invention provides a topical, foamable composition characterised in that upon application to the skin of a user a penetration of at least 30μg/cm2 is achieved in the epidermis within one hour of application and sustained over a period of at least 23 hours.
When the preferred active agent is chlorphenesin, the invention provides a topical, foamable composition characterised in that upon application to the skin of a user a penetration of at least 10μg/cm2 is achieved in the epidermis within one hour of application and sustained over a period of at least 23 hours. In a still further aspect of the invention, there is provided a method of treating fungal infections, particularly tinea, jock itch, dandruff and sebborheic dermatitis by applying to the affected area of a patient requiring such treatment the antifungal composition of the present invention.
In a preferred embodiment of this aspect of the invention, the composition is allowed to remain on the affected area for an extended period of time.
In this context "extended period of time" means a length of time greater than the length of time that prior art topical compositions such as shampoos are prescribed to remain in contact with the affected area. Usually, shampoos are designed to be washed off within 5 minutes. More preferably, when the composition is used to treat dandruff or sebborheic dermatitis, it is applied at one wash or between washes and is allowed to remain on the site of application such as the scalp or hair until the site of application is subsequently washed again.
The invention also encompasses the use of an antifungal agent in the preparation of a topical foamable composition for the treatment of fungal diseases including dandruff, tinea, jock itch and sebborheic dermatitis, the topical foamable composition being characterised in that it is able to penetrate
the epidermis of the skin and is retained in or on an area to be treated for a prolonged period of time, and in that it has a non-volatile component content of less that 25%. Detailed Description of the Invention
Two formulations of the present invention were prepared.
1 )
Cetyl alcohol 1.10
Stearyl alcohol 0.50
Quaternium 52 (50%) 1.00
Propylene Giycol 2.00
Ketoconazole USP 0.50
Ethanol 95PGF3 60.55
Deionised Water 30.05
P75 Hydrocarbon Propellant 4.30 2) 1 % ketoconazole mousse com Dosition
Cetyl alcohol 1.10
Stearyl alcohol 0.50
Quaternium 52 (50%) 1.00
Propylene Giycol 2.00 Ketoconazole USP 1.00
Ethanol 95PGF3 60.20
Deionised Water 29.90
P75 Hydrocarbon Propellant 4.30 The compositions were prepared by dissolving the active in the ethanol. the cetyl and stearyl alcohol are then added to the heated solution and mixed until dissolved. The quaternium 52, propylene giycol and water are then added and stirred until homogenous, while maintaining the elevated temperature. The solution is then dispensed into aerosol cans where the aerosol valve is then fitted and the can charged with propellant. EXAMPLE 1
A study was undertaken to compare the epidermal penetration of the two mousse compositions above, against the commercially available Nizoral®
shampoo containing 2% ketoconazole. In particular the respective formulations were applied and removed as for a conventional shampoo so as to compare the penetration of the respective formulations into the epidermis. Equipment and Materials in vitro Franz diffusion cells (surface area 1.33 cm2, receptor volume
3.5ml) incorporating human epidermis
HPLC equipment: Shimadzu automated HPLC system with uv detector, bovine serum albumin dissolved in phosphate buffered saline (pH 7.4) as receptor phase to mimic physiological conditions. Experimental Protocol finite dosing (50mg for shampoo and 100mg for mousses) receptor phase: 4% BSA in phosphate buffered saline at pH 7.4 sampling time: 6,10,24 hours (amount in receptor phase (μg/cell) and epidermis(μg/cell)) non-occlusion study each time period and formulation conducted in triplicate.
Application Procedure Shampoo: 50 mg shampoo (equivalent to 1 mg ketoconazole) dose applied to pre-wetted skin with stirring and rinsed off with deionised water after 4 minutes. Mousse: 100 mg mousse (equivalent to 1 mg ketoconazole for 1 % mousse and 500 μg ketoconazole for 0.5% mousse dose applied (not rinsed off). Epidermal retention protocol
Epidermis removed from cell following time interval, rinsed with distilled water and dried to remove ketoconazole remaining on surface. Ketoconazole extracted from epidermal sample by soaking in methanol for 1 hour. This procedure is repeated with a second volume of methanol for 30 mins. The methanol samples are combined for HPLC analysis (this procedure has been validated with a 99% recovery rate). HPLC assay
Column: Nova Pak C-is steel column, 3.9 x 150 mm
Mobile phase: 70% MeOH in 0.02 M phosphate buffer, pH 6.8
Wavelength: 254 nm
Flow rate: 1.3 ml/min
Injection volume: 10 μl Retention time: about 7 min Results
Table 1 shows the cumulated ketoconazole in both the receptor phase and the epidermis at defined time points following application of the mousse according to the invention and the shampoo of the prior art.
TABLE 1
Ketoconazole μg/cell
6 hours 10 hours 24 hours
Sample receptor epidermis -"receplor epidermis receptor epidermis
0.5% 4.96 33.15 9.04 69.46 14.69 42.10 mousse
0.5% 2.83 35.71 18.06 48.04 24.77 39.19 moi e
0.5% 14.37 34.3 21.3 55.29 9.82 48.27 mousse
Meart±SD 7.4±6.1 34.4±1.3 16.U6.4 57.6i10.9 16.4±7.6 43.2±4.6
1 % mousse 12.86 46.4 31.50 67.51 21.90 51.43
1 % mousse 10.03 61.8 11.05 55.65 35.35 46.64
1 % mousse 18.61 38.6 19.38 56.83 10.72 43.28
MeaniSD 13.8±4.4 48.9±11.e 20^.6*10.3 60±6.5 22.3U2.6 47. U4.1
2% shampoo N N N 0.89 N N
2% shampoo N N N 0.28 N 0.38
2% shampoo N N N N N 0.34
Mean±SO - - 0.39:10.46 - 0.24rO.21
N: not detectable (assuming to be zero for calculating mean and SD) -: not available
Table 2 shows the cumulated ketoconazole in both receptor (expressed as μg/ml receptor fluid) and epidermis (expressed as μg/cm2 surface area) at defined time points following application of the mousse according to the present invention and the shampoo of the prior art.
TABLE 2
Ketoconazole μg
S hours 10 hours 24 hours
Sample receptor epidermis receptor epidermis receptor epidermis
0.5% 1.42 26.95 2.58 56.47 4.20 34.23 mousse
0.5% 0.81 29.03 5.4.6 39.06 7.08 31.86 mousse
0.5% 4.11 27.89 6.09 44.95 2.81 39.24 mousse
Mean±SD 2.1 1±1.76 27.95±1.04 4.6 1.82 46.83+8.86 4.70±2.18 35.11±3.77
1 % mousse 3.67 37.72 9.00 54.89 6.26 41.81
1 % mousse 2.87 50.24 3.16 45.24 10.24 37.92
1 % mousse 5.32 31.38 5.54 46.20 3.06 35.19
Mean±SD 3.95±1.25 39.78±9.G0 0.90=2.94 48.78t5.31 Θ.52±3.β0 38.31±3.33
2% shampoo N M N 0.72 N N
2% shampoo N N N 0.23 N 0.31
2% shampoo N N N N N 0.28
Mean±SD - - 0.32±0.37 - 0.2010.17
N: not detectable (assuming to be zero for calculating mean and SD) -: not available
Figure 1 shows the time course of the ketoconazole penetrating across human epidermis to receptor fluid. The closed points of the graph represent 0.5% mousse, the open points represent 1.0% mousse. Data are the mean ± SD of triplicate (from Table 2). Figure 2 represents the time course of ketoconazole retained in the epidermis. The closed points of the graph represent 0.5% mousse, the open points represent 1.0% mousse. Data are the mean ± SD of triplicate (from Table 2).
Figure 3 compares the levels of retention of ketoconazole on the skin, the levels of retention of the ketoconazole in the skin and the amount of ketoconazole passed through the skin in the tests using a mousse according to the invention with the same measures using Nizoral®. Note that ketoconazole levels found after application of the Nizoral® shampoo were low and thus are not visible in this figure It can readily be observed from the results of example 1 that:
1. the ketoconazole in the mousse compositions of the present invention penetrated the skin in appreciable quantity;
2. the ketoconazole in the mousse composition of the present invention was preferentially retained in the epidermis compared to penetration into the receptor solution;
3. application of the prior art shampoo, Nizoral®, resulted in insignificant amounts of ketoconazole in the epidermis and penetrating to the receptor phase at any of the time points following application using a standardised shampooing procedure; 4. comparison of the 1 % and 0.5% mousse formulations of the present invention shows that there is little difference in epidermal and receptor phase concentrations. EXAMPLE 2
A second study was undertaken to compare the skin penetration and retention of ketoconazole from the 1 % ketoconazole mousse composition of the current invention with Nizoral® Shampoo (1 %w/w). The 1 % mousse composition had a total residue content of 5.1% solids including active.
Equipment and Materials
In vitro Franz diffusion cells (surface area 1.33 cm2, receptor volume 3.5 mL) incorporating full thickness human skin,
HPLC equipment: Shimadzu automated HPLC system with uv detector. Experimental protocol
Finite dosing (50 mg of each formulation placed onto skin surface),
Receptor phase: 4% bovine serum albumin (BSA) in phosphate buffered saline
(PBS) pH 7.4,
Sampling times for skin retention: 15 minutes, 1 , 12, 24 hours, Sampling times for skin penetration to receptor phase: 12, 24 hours,
Amount of ketoconazole in full thickness skin and receptor phase measured by
HPLC assay following suitable extraction procedure,
Non-occlusion study,
Triplicate measurements. Application procedure
Both mousse and shampoo were applied and left in contact with the skin for the duration of the penetration study. Following this the formulation was washed off the skin with distilled water prior to sample extraction procedure and
HPLC assay for ketoconazole content. HPLC assay
Column: Nova Pac Cιs steel column, 3.9 x 150 mm (Waters)
Mobile phase: 70% MeOH in 0.02M PBS, pH 6.8
Wavelength: 254 nm
Flow rate: LO mUmin Injection volume: 10 μL
Retention time: approximately 8 mins
Full thickness skin retention protocol
Full thickness skin was removed from cell following time interval, rinsed with distilled water and dried to remove ketoconazole remaining on surface. Ketoconazole was extracted from full thickness skin sample by soaking in methanol for 1 hour. This procedure was repeated with a second volume of methanol for 30 mins. The methanol samples were combined from HPLC
analysis. [This procedure has been validated with a 99% recovery rate].
Results
Figure 4 shows the HPLC standard curve for ketoconazole.
Table 3 shows the amount of ketoconazole retained in the skin (μg/cm2) at 15, 60 minutes, 12 and 24 hours following application of the mousse according to the invention, or the shampoo of the prior art.
Table 3, Ketoconazole retained in skin (μg/cm2) at 15, 60 mins, 12, 24 hours following application of mousse or shampoo.
Table 4 shows the amount of Ketoconazole penetrated to the receptor phase (μg/mL) at 12, 24 hours following application of the mousse according to the invention, or the shampoo of the prior art.
Table 4, Ketoconazole penetrated to receptor phase (μg/mL) at 12, 24 hours following application of mousse or shampoo.
n: not detectable -: not assayed
Figure 5 shows the amount of ketoconazole retained in the skin versus the time after application of the formulation according to the invention. Data are the mean ±SEM (n=3) from Table 4.
The mousse formulation according to the invention demonstrated
significantly greater skin retention of ketoconazole than the shampoo formulation of the prior art over the 24 hour period.
It can readily be observed from the results of example 2 that:
1. penetration of ketoconazole to the receptor phase over the 24 hours following application was minimal for both shampoo and mousse.
2. skin retention of ketoconazole was significantly greater following application of the mousse formulation compared to the shampoo (p<0.05).
EXAMPLE 3 A third study was undertaken to compare the skin penetration and retention of two formulations according to the invention in which the active anti fungal agent was chlorphenesin (0.5% w/w). One formulation was ethanolic and had a total residue content of 2.5% solids including active, the other formulation was aqueous and had a total residue content of 4.6% solids including active.
Aqueous formulation %w/w
Chlorphenesin 0.50
Cetyl alcohol 0.70
Stearyl alcohol 0.30 lcocetyl alcohol 2.50
Ceteth 20 0.50
Preservative 0.10
Purified Water 90.40
P75 Hydrocarbon Propellant 5.00
Ethanolic formulation
Chlorphenesin 0.50
Cetyl alcohol 1.10
Stearyl alcohol 0.50
Polysorbate 0.40
Ethanol 95% 60.79
Purified Water 32.41
P75 Hydrocarbon Propellant 4.30
Equipment and Materials
In vitro Franz diffusion cells (surface area 1.33 cm2, receptor volume 3.5 mL) incorporating full thickness human skin,
HPLC equipment: Shimadzu automated HPLC system with uv detector.
Experimental protocol Finite dosing (50 mg of each formulation placed onto skin surface),
Receptor phase: 4% bovine serum albumin (BSA) in phosphate buffered saline
(PBS) pH 7.4,
Sampling times for skin retention: 15 minutes, 1 , 12, 24 hours,
Sampling times for skin penetration to receptor phase: 12, 24 hours, Amount of chlorphenesin in full thickness skin and receptor phase measured by
HPLC assay following extraction into acetonitrile (ACN) and methanol (MeOH)
(9:1 ),
Non-occlusion study,
Triplicate measurements. Application
Mousses according to the invention were applied and left in contact with the skin for the duration of the penetration study. Following this the formulation was washed off with distilled water prior to the extraction and HPLC fo chlorphenesin content. HPLC assay
Column: Nova Pac Cιβ steel column, 3.9 x 150 mm (Waters)
Mobile phase: 30% ACN
Wavelength: 280 nm
Flow rate: 1.0 mL/min Injection volume: 20 μL
Retention time: approximately 3.6 mins
Skin Retention Protocol
Skin was removed form the cell following time interval and rinsed with distilled water to remove chlorphenesin on the surface. Chlorphenesin was extracted from homogenised skin by soaking in 1 mL ACN-MeOH mix for 1 hour. This procedure was repeated for a further four 30 minute periods. The five samples were combined for HPLC analysis. [The procedure was validated with a 99%
recovery rate]. Results
Figure 6 shows the HPLC standard curve for chlorphenesin. Data are the mean ± standard deviation (n=3).
Table 5 shows the amount of chlorphenesin retained in the skin (μg/cm2) at 15, 60 minutes, 12 and 24 hours following application of the mousse according to the invention. Table 5
Table 6 shows the amount of chlorphenesin penetrated to the receptor phase (μg/mL) at 12, 24 hours following application of the mousse according to 10 the invention. Table 6
:- not assayed
Figure 7 shows the amount of chlorphenesin retained in the skin versus the time after application of the formulation according to the invention. Data are the mean ± standard deviation (n=3) from Table 5. The open points are the aqueous formulation. The closed points represent the ethanolic formulation. 15 It is readily observed from the results of example 3 that active agents other than ketoconazole formulated as both ethanolic and aqueous compositions achieve the desired penetration and retention levels for effective treatment of fungal skin conditions.
It will be appreciated that the scope of this invention goes beyond the specific formulations exemplified to encompass topical foamable antifungal compositions having like components to those specifically mentioned but having characteristic penetration and retention levels in the skin of the user, and low levels of residual solid content as defined.
Claims
1. A topical, foamable composition including at least one antifungal agent, said composition characterised in that said at least one antifungal agent is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and in that it has a residual non-volatile component content of less than 25%.
2. The composition as claimed in claim 1 which has a residual non-volatile component content of less than 10%.
3. The composition as claimed in claim 1 or 2 which has a residual non- volatile component content of less than 6%.
4. The composition as claimed in any one of claims 1 -3 which is a mousse.
5. The composition as claimed in claim 4 wherein the mousse is a temperature sensitive mousse which breaks down rapidly when exposed to the skin temperature.
6. The composition as claimed in any one of claims 1-5 which is ethanolic.
7. The composition as claimed in any one of claims 1 -5 which is aqueous.
8. The composition as claimed in any one of claims 1-6 including a lower alcohol content of greater than 10% and a hydrocarbon gas content propellent of less than 60%.
9. The composition as claimed in any one of claims 1 -5 and 7 including a hydrocarbon gas content propellent of less than 60%.
10. The composition as claimed in any one of claims 1 -9 including up to 5% of long chain alcohols up to 5% of quaternary compound up to 10% of propylene giycol up to 5% of antifungal agent up to 90% of lower alcohol solvent up to 5% of surfactant 5-95% of water, and up to 20% of a hydrocarbon gas propellant
11. The composition as claimed in any one of claims 1 -10 in which the at least one antifungal agent is selected from the group consisting of diols, allylamines (including naftifine and terbinafine), polyene macrolide antibiotics (including amphotericin and nystatin), triazole derivatives (such as fluconazole), fatty acids (such as caprylic and propionic acid), amorolfine, ciclopirox, olamine, benzoic acid, flucytosine, haloprogin, tolnaftate, undecenoic acid and its salts, griseofulvin and imidazole compounds.
12. The composition as claimed in any one of claims 1 -1 1 in which the antifungal is an imidazole compound.
13. The composition as claimed in any one of claims 1 -1 1 in which the antifungal agent is ketoconazole or chlorphenesin.
14. A composition for the treatment of fungal skin conditions including jock itch, tinea, dandruff and seborrheic dermatitis, said composition characterised in that it is a foamable mousse applicable to the skin of the user in the substantial absence of water and without substantially immediate removal by washing.
15. The composition as claimed in claim 14 having a non-volatile component content of less than 25%.
16. The composition as claimed in claim 14 having a non-volatile component content of less than 10%.
17. The composition as claimed in claim 14 having a non-volatile component content of less than 6%.
18. The composition as claimed in any one of claims 14-17 wherein the mousse is a temperature sensitive mousse which breaks down rapidly when exposed to the skin temperature.
19. The composition as claimed in any one of claims 14-18 which is ethanolic.
20. The composition as claimed in any one of claims 14-18 which is aqueous.
21. The composition as claimed in any one of claims 14-19 including a lower alcohol content of greater than 10% and a hydrocarbon gas content propellent of less than 60%.
22. The composition as claimed in any one of claims 14-18 and 20 including a hydrocarbon gas content propellent of less than 60%.
23. The composition as claimed in any one of claims 14-22 including up to 5% of long chain alcohols up to 5% of quaternary compound up to 10% of propylene giycol up to 5% of antifungal agent up to 90% of lower alcohol solvent up to 5% of surfactant
5-95% of water, and up to 20% of a hydrocarbon gas propellant
24. The composition as claimed in any one of claims 14-23 in which the at least one antifungal agent is selected from the group consisting of diols, allylamines (including naftifine and terbinafine), polyene macrolide antibiotics (including amphotericin and nystatin), triazole derivatives (such as fluconazole), fatty acids (such as caprylic and propionic acid), amorolfine, ciclopirox, olamine, benzoic acid, flucytosine, haloprogin, tolnaftate, undecenoic acid and its salts, griseofulvin and imidazole compounds.
25. The composition as claimed in any one of claims 14-23 in which the antifungal is an imidazole compound.
26. The composition as claimed in any one of claims 14-23 in which the antifungal agent is ketoconazole or chlorphenesin.
27. A topical, foamable composition including an antifungal agent characterised in that upon application to the skin of a user a penetration of at least 10╬╝g/cm2 is achieved in the epidermis within one hour of application and sustained over a period of at least 23 hours.
28. A composition as claimed in claim 27 wherein the antifungal agent is ketoconazole and a penetration of at least 30╬╝g/cm2 is achieved in the epidermis within one hour of application and sustained over a period of at least 23 hours.
29. A composition as claimed in claim 27 wherein the antifungal agent is chlorphenesin and a penetration of at least 10╬╝g/cm2 is achieved in the epidermis within one hour of application and sustained over a period of at least 23 hours.
30. A method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis by applying to the affected area of a patient requiring such treatment the antifungal composition as claimed in any one of claims 1-29.
31. The use of an antifungal agent in the preparation of a topical foamable composition for the treatment of fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis, the topical foamable composition being characterised in that it is able to penetrate the epidermis of the skin and is retained in or on an area to be treated for a prolonged period of time, and in that it has a non-volatile component content of less than 25%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06002782A EP1692951A1 (en) | 1997-10-17 | 1998-10-19 | Topical antifungal composition |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO983897 | 1997-10-17 | ||
| AUPO9838A AUPO983897A0 (en) | 1997-10-17 | 1997-10-17 | Topical antifungal composition |
| AUPP121798 | 1998-01-06 | ||
| AUPP1217A AUPP121798A0 (en) | 1997-10-17 | 1998-01-06 | Topical antifungal composition |
| PCT/AU1998/000867 WO1999020250A1 (en) | 1997-10-17 | 1998-10-19 | Topical antifungal composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06002782A Division EP1692951A1 (en) | 1997-10-17 | 1998-10-19 | Topical antifungal composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP1024792A1 true EP1024792A1 (en) | 2000-08-09 |
| EP1024792A4 EP1024792A4 (en) | 2001-08-08 |
| EP1024792B1 EP1024792B1 (en) | 2006-11-29 |
Family
ID=25645634
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP98951104A Expired - Lifetime EP1024792B1 (en) | 1997-10-17 | 1998-10-19 | Topical antifungal composition |
| EP06002782A Withdrawn EP1692951A1 (en) | 1997-10-17 | 1998-10-19 | Topical antifungal composition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06002782A Withdrawn EP1692951A1 (en) | 1997-10-17 | 1998-10-19 | Topical antifungal composition |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US7553835B1 (en) |
| EP (2) | EP1024792B1 (en) |
| JP (1) | JP4917204B2 (en) |
| AT (1) | ATE346588T1 (en) |
| AU (3) | AUPO983897A0 (en) |
| CA (1) | CA2306560C (en) |
| CY (1) | CY1106021T1 (en) |
| DE (1) | DE69836555T2 (en) |
| DK (1) | DK1024792T3 (en) |
| ES (1) | ES2277394T3 (en) |
| PT (1) | PT1024792E (en) |
| WO (1) | WO1999020250A1 (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9504265D0 (en) | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
| AUPO983897A0 (en) | 1997-10-17 | 1997-11-06 | Soltec Research Pty Ltd | Topical antifungal composition |
| CA2319099C (en) * | 1998-02-13 | 2009-03-24 | Carol J. Buck | Compositions and methods of treating keratin-related disorders and conditions |
| AUPP310798A0 (en) | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
| US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
| US6358541B1 (en) | 2000-05-03 | 2002-03-19 | David S. Goodman | Topical preparation for the treatment of hair loss |
| GB2365770B (en) * | 2000-08-18 | 2002-07-31 | Diomed Dev Ltd | Antifungal ketoconazole composition for topical use |
| AUPR048600A0 (en) * | 2000-10-02 | 2000-10-26 | Soltec Research Pty Ltd | Pharmaceutical vehicle |
| US6696048B2 (en) | 2001-12-20 | 2004-02-24 | Schering-Plough Healthcare Products, Inc. | Sunscreen composition |
| US6835385B2 (en) | 2002-06-14 | 2004-12-28 | Carol J. Buck | Compositions and methods for softening, thinning and removing hyperkeratotic tissue |
| US6858215B2 (en) | 2002-06-14 | 2005-02-22 | Carol J. Buck | Compositions and methods for softening, thinning and removing hyperkeratotic tissue |
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| EP1556009B2 (en) | 2002-10-25 | 2021-07-21 | Foamix Pharmaceuticals Ltd. | Cosmetic and pharmaceutical foam |
| US20050186142A1 (en) * | 2002-10-25 | 2005-08-25 | Foamix Ltd. | Kit and composition of imidazole with enhanced bioavailability |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| MXPA05007722A (en) * | 2003-01-24 | 2006-01-31 | Connetics Australia Pty Ltd | Clindamycin phosphate foam. |
| US7186416B2 (en) | 2003-05-28 | 2007-03-06 | Stiefel Laboratories, Inc. | Foamable pharmaceutical compositions and methods for treating a disorder |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| WO2006103638A2 (en) * | 2005-03-31 | 2006-10-05 | Ranbaxy Laboratories Limited | Topical pharmaceutical compositions of terbinafine and processes for their preparation |
| JP5612263B2 (en) | 2005-06-01 | 2014-10-22 | スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド | Vitamin preparation |
| EP2010133B1 (en) | 2006-03-31 | 2016-05-04 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| FR2915097B1 (en) * | 2007-04-18 | 2012-09-28 | Fabre Pierre Dermo Cosmetique | ANTIFUNGAL FOAM BASED ON CICLOPIROXOLAMINE AND ZINC PYRITHIONE AND ITS MEDICAL AND COSMETIC APPLICATIONS. |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
| WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
| US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
| WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| ES2424294B1 (en) * | 2012-03-22 | 2014-07-21 | Lipotec, S.A. | Exopolysaccharide for the treatment and / or care of skin, mucous membranes, hair and / or nails |
| FR3009954B1 (en) * | 2013-08-29 | 2015-09-25 | Oreal | SPRAYABLE FOAM-FORMING COSMETIC COMPOSITION COMPRISING ANTIPELLICULAR AGENT, A CATIONIC POLYMER, A SURFACTANT AND A PROPELLANT |
| US20190282501A1 (en) * | 2016-01-29 | 2019-09-19 | Foamix Pharmaceuticals Ltd. | Hydroalcoholic foam formulations of naftifine |
| MX2020012139A (en) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Compositions and methods for treating rosacea and acne. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0156508A1 (en) * | 1984-02-23 | 1985-10-02 | Ortho Pharmaceutical Corporation | Antifungal aerosol solution |
| FR2740685A1 (en) * | 1995-11-08 | 1997-05-09 | Pf Medicament | FOAMING TOPICAL PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOSES INDUCED BY PITYROSPORUM OVAL |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3131152A (en) | 1960-06-13 | 1964-04-28 | Allied Chem | Foam producing formulations |
| US3330730A (en) | 1962-08-03 | 1967-07-11 | Colgate Palmolive Co | Pressurized emulsion quick breaking foam compositions |
| US3824303A (en) | 1963-07-24 | 1974-07-16 | Yardley Of London Inc | Collapsible foam pre-electric shave lotion containing diester lubricants |
| US3395214A (en) | 1964-01-09 | 1968-07-30 | Scholl Mfg Co Inc | Antiperspirant composition providing a readily collapsible sprayable foam |
| AU411950B1 (en) | 1966-05-30 | 1971-03-31 | Yardley & Company, Limited | Self-propelled homogeneous liquid compositions |
| JPS504650B2 (en) * | 1971-09-03 | 1975-02-22 | ||
| JPS5715147B2 (en) | 1972-03-09 | 1982-03-29 | ||
| LU66207A1 (en) * | 1972-09-29 | 1974-04-02 | ||
| US4144346A (en) | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| US4491588A (en) | 1982-03-31 | 1985-01-01 | University Of Tennessee Research Corporation | Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics |
| US4942162A (en) | 1982-03-31 | 1990-07-17 | University Of Tennessee Research Corporation | Topical treatment of seborrheic dermatitis with ketoconazole |
| US4569935A (en) | 1983-03-17 | 1986-02-11 | University Of Tennessee Research Corp. | Topical treatment of psoriasis with imidazole antibiotics |
| JPS59184135A (en) * | 1983-04-04 | 1984-10-19 | Teijin Ltd | Medicinal composition containing glycerol pyroglutamate |
| AU565146B2 (en) | 1983-10-24 | 1987-09-03 | Connetics Australia Pty Ltd | Foamable biocide composition |
| WO1986000196A1 (en) | 1984-06-21 | 1986-01-16 | Soltec Research Pty. Ltd. | Aerosol product |
| US4775678A (en) | 1984-10-01 | 1988-10-04 | Schering Corporation | Clotrimazole cream |
| US4806262A (en) * | 1985-08-14 | 1989-02-21 | The Procter & Gamble Company | Nonlathering cleansing mousse with skin conditioning benefits |
| JPS6254784A (en) * | 1985-09-04 | 1987-03-10 | Osaka Eyazoole Kogyo Kk | Aerosol composition |
| AU8025787A (en) | 1986-09-12 | 1988-04-07 | Upjohn Company, The | Foams for delivery of minoxidil |
| US4882182A (en) | 1987-01-08 | 1989-11-21 | Soltec Research Pty. Ltd. | Aerosol product |
| US4828837A (en) | 1987-03-30 | 1989-05-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition, its production and application |
| FR2616065A1 (en) * | 1987-06-02 | 1988-12-09 | Pabst Jean Yves | Quaternary ammonium-based pharmaceutical aerosol |
| JP2810041B2 (en) | 1987-09-09 | 1998-10-15 | 株式会社資生堂 | Hair restorer for scalp and hair |
| JP2810040B2 (en) | 1987-09-09 | 1998-10-15 | 株式会社資生堂 | Hair restorer for scalp and hair |
| JPH0745387B2 (en) | 1987-09-09 | 1995-05-17 | 株式会社資生堂 | Hair growth and hair growth promoter |
| US4888354A (en) | 1987-12-21 | 1989-12-19 | Theratech, Inc. | Skin penetration enhancement using free base and acid addition salt combinations of active agents |
| AU619256B2 (en) | 1988-03-03 | 1992-01-23 | Connetics Australia Pty Ltd | Acne treatment |
| US5008293A (en) * | 1988-07-22 | 1991-04-16 | Berger Frank M | Process for the treatment of the skin to alleviate skin diseases arising from contact sensitization or irritation utilizing p-substituted phenoxy alkanols |
| LU87449A1 (en) | 1989-02-09 | 1990-09-19 | Oreal | PROCESS FOR THE MANUFACTURE OF FOAMS FOR USE IN THE COSMETIC AND PHARMACEUTICAL AREAS AND FOAMS OBTAINED BY THIS PROCESS |
| DK0414920T3 (en) | 1989-03-17 | 1997-12-15 | Taisho Pharmaceutical Co Ltd | Aerosol preparations for external use |
| DE69020900T2 (en) * | 1989-07-28 | 1995-12-14 | Hisamitsu Pharmaceutical Co | FOAM AEROSOL COMPOSITION. |
| US5219877A (en) | 1989-09-25 | 1993-06-15 | Bristol-Myers Squibb Company | Lauryl alcohol as skin penetration enhancer for topical imidazole agents |
| IL95952A0 (en) * | 1989-10-19 | 1991-07-18 | Sterling Drug Inc | Aerosol composition for topical medicament |
| US6469015B1 (en) * | 1990-01-26 | 2002-10-22 | Novartis International Pharmaceutical Ltd | Pharmaceutical formulation |
| US5156765A (en) * | 1990-05-15 | 1992-10-20 | Fox Valley Systems, Inc. | Aerosol foam marking compositions |
| GB9014221D0 (en) * | 1990-06-26 | 1990-08-15 | Janssen Pharmaceutica Nv | Method of treating alopecia |
| DE69117762T2 (en) | 1990-08-10 | 1996-08-08 | The Upjohn Company, Kalamazoo, Mich. | STIMULATING HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND 5-ALPHA REDUCTASE INHIBITORS |
| US5935554A (en) | 1990-09-03 | 1999-08-10 | Soltec Research Pty. Ltd. | Concentrated aerosol space spray that is not an emulsion |
| JP3140460B2 (en) | 1990-09-03 | 2001-03-05 | ソルテック リサーチ プロプライアタリィ リミティド | Concentrated aerosol space spray |
| US5167950A (en) * | 1991-03-28 | 1992-12-01 | S. C. Johnson & Son | High alcohol content aerosol antimicrobial mousse |
| JP2555555B2 (en) * | 1991-07-03 | 1996-11-20 | 武田薬品工業株式会社 | Antifungal topical formulation |
| GB9205194D0 (en) | 1992-03-10 | 1992-04-22 | Smithkline Beecham Plc | Novel composition |
| ZA94170B (en) | 1993-01-20 | 1995-03-15 | Soltec Res Pty Ltd | Ectoparasiticidal formulation |
| ES2064288B1 (en) | 1993-07-06 | 1995-08-01 | Ornosa Enrique Viayna | COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS, THEIR PREPARATION AND USE. |
| US5456851A (en) * | 1994-04-07 | 1995-10-10 | Johnson & Johnson Consumer Products, Inc. | Ketoconazole shampoo containing butylated hydroxytoluene or butylated hydroxyanisole |
| US5679324A (en) * | 1994-07-08 | 1997-10-21 | The Procter & Gamble Co. | Aerosol foamable fragrance composition |
| JPH0840899A (en) | 1994-07-29 | 1996-02-13 | Tokyo Tanabe Co Ltd | Aerosol of oxyconazone nitrate |
| TW460296B (en) | 1994-09-01 | 2001-10-21 | Janssen Pharmaceutica Nv | Topical ketoconazole emulsion compositions without sodium sulfite |
| US5776430A (en) * | 1994-11-01 | 1998-07-07 | Calgon Vestal, Inc. | Topical antimicrobial cleanser containing chlorhexidine gluconate and alcohol |
| JP3881400B2 (en) * | 1995-02-22 | 2007-02-14 | 久光製薬株式会社 | Aerosol composition and aerosol-type external preparation |
| GB9504265D0 (en) | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
| US5783202A (en) | 1995-03-14 | 1998-07-21 | Soltec Research Pty. Ltd. | Pediculicidal mousse composition for killing head lice |
| JP3518096B2 (en) | 1995-09-29 | 2004-04-12 | 松下電器産業株式会社 | Method of manufacturing video recording and playback equipment |
| JPH09188629A (en) | 1996-01-06 | 1997-07-22 | Pola Chem Ind Inc | Medicine for inhibiting antibody-producing cell and composition containing the same |
| US5788155A (en) | 1996-06-28 | 1998-08-04 | S. C. Johnson & Son, Inc. | Air freshener dispenser device with dual cartridge capacity |
| JP3061575B2 (en) | 1996-10-17 | 2000-07-10 | 日立建機株式会社 | Drilling rig |
| AUPO379596A0 (en) | 1996-11-22 | 1996-12-19 | Soltec Research Pty Ltd | Percutaneous delivery system |
| JPH10158782A (en) | 1996-12-05 | 1998-06-16 | Nkk Corp | Steel sheet for shadow mask excellent in pierceability and press formability at the time of photo etching and its production |
| JPH10265343A (en) | 1997-01-23 | 1998-10-06 | Taisho Pharmaceut Co Ltd | Sustained release hair growing agent |
| KR20000070370A (en) | 1997-01-23 | 2000-11-25 | 우에하라 아끼라 | Persistent Hair Tonic |
| AUPO688997A0 (en) | 1997-05-20 | 1997-06-12 | Soltec Research Pty Ltd | Sunscreen composition |
| AUPO983897A0 (en) | 1997-10-17 | 1997-11-06 | Soltec Research Pty Ltd | Topical antifungal composition |
| US6231875B1 (en) | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
| AUPP310798A0 (en) | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
| US6284234B1 (en) | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
| AUPP583198A0 (en) | 1998-09-11 | 1998-10-01 | Soltec Research Pty Ltd | Mousse composition |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| AUPQ002999A0 (en) | 1999-04-29 | 1999-05-20 | Soltec Research Pty Ltd | Non-aqueous shampoo composition |
| US6373471B1 (en) * | 1999-12-16 | 2002-04-16 | Silitek Corporation | Keyboard with interchangeable connection function |
| IT1309735B1 (en) * | 1999-12-27 | 2002-01-30 | Olivetti Lexikon Spa | INK MULTIPLE CHANNEL HEAD |
| JP4780429B2 (en) | 2000-04-07 | 2011-09-28 | 大正製薬株式会社 | Minoxidil-containing preparation |
| ATE305765T1 (en) | 2000-04-07 | 2005-10-15 | Taisho Pharmaceutical Co Ltd | HAIR GROWTH PROMOTING COMPOSITIONS |
-
1997
- 1997-10-17 AU AUPO9838A patent/AUPO983897A0/en not_active Abandoned
-
1998
- 1998-01-06 AU AUPP1217A patent/AUPP121798A0/en not_active Abandoned
- 1998-10-19 JP JP2000516650A patent/JP4917204B2/en not_active Expired - Lifetime
- 1998-10-19 EP EP98951104A patent/EP1024792B1/en not_active Expired - Lifetime
- 1998-10-19 AU AU97288/98A patent/AU732456B2/en not_active Expired
- 1998-10-19 US US09/529,033 patent/US7553835B1/en not_active Expired - Fee Related
- 1998-10-19 DE DE69836555T patent/DE69836555T2/en not_active Expired - Lifetime
- 1998-10-19 ES ES98951104T patent/ES2277394T3/en not_active Expired - Lifetime
- 1998-10-19 WO PCT/AU1998/000867 patent/WO1999020250A1/en active IP Right Grant
- 1998-10-19 CA CA002306560A patent/CA2306560C/en not_active Expired - Lifetime
- 1998-10-19 DK DK98951104T patent/DK1024792T3/en active
- 1998-10-19 PT PT98951104T patent/PT1024792E/en unknown
- 1998-10-19 AT AT98951104T patent/ATE346588T1/en active
- 1998-10-19 EP EP06002782A patent/EP1692951A1/en not_active Withdrawn
-
2007
- 2007-02-15 CY CY20071100206T patent/CY1106021T1/en unknown
-
2008
- 2008-12-02 US US12/293,000 patent/US8026238B2/en not_active Expired - Fee Related
-
2011
- 2011-06-21 US US13/165,224 patent/US8586066B2/en not_active Expired - Fee Related
- 2011-06-21 US US13/165,282 patent/US20110251146A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0156508A1 (en) * | 1984-02-23 | 1985-10-02 | Ortho Pharmaceutical Corporation | Antifungal aerosol solution |
| FR2740685A1 (en) * | 1995-11-08 | 1997-05-09 | Pf Medicament | FOAMING TOPICAL PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOSES INDUCED BY PITYROSPORUM OVAL |
Non-Patent Citations (2)
| Title |
|---|
| FALBE J; REGITZ M: "Römpp Chemie Lexikon" 1995, GEORG THIEME , STUTTGART (GERMANY) * page 1337 - page 1338 * * |
| See also references of WO9920250A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69836555T2 (en) | 2007-09-27 |
| PT1024792E (en) | 2007-01-31 |
| AU9728898A (en) | 1999-05-10 |
| WO1999020250A1 (en) | 1999-04-29 |
| CY1106021T1 (en) | 2011-04-06 |
| AUPP121798A0 (en) | 1998-01-29 |
| CA2306560A1 (en) | 1999-04-29 |
| DK1024792T3 (en) | 2007-01-15 |
| US20090149473A1 (en) | 2009-06-11 |
| CA2306560C (en) | 2009-07-14 |
| EP1692951A1 (en) | 2006-08-23 |
| AUPO983897A0 (en) | 1997-11-06 |
| US20120070384A1 (en) | 2012-03-22 |
| JP2001520184A (en) | 2001-10-30 |
| JP4917204B2 (en) | 2012-04-18 |
| EP1024792A4 (en) | 2001-08-08 |
| EP1024792B1 (en) | 2006-11-29 |
| ATE346588T1 (en) | 2006-12-15 |
| US8586066B2 (en) | 2013-11-19 |
| US8026238B2 (en) | 2011-09-27 |
| AU732456B2 (en) | 2001-04-26 |
| ES2277394T3 (en) | 2007-07-01 |
| US20110251146A1 (en) | 2011-10-13 |
| US7553835B1 (en) | 2009-06-30 |
| DE69836555D1 (en) | 2007-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2306560C (en) | Topical antifungal composition | |
| US10363216B2 (en) | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof | |
| EP1633368B1 (en) | Foamable pharmaceutical compositions and methods for treating a disorder | |
| DK1695708T3 (en) | Highly concentrated minoxidil composition | |
| CA2444533C (en) | Pharmaceutical vehicle | |
| EP0728462B1 (en) | Cosmetic method and composition for treating hair loss | |
| IE913469A1 (en) | Novel composition | |
| PL212984B1 (en) | Formulations containing melatonin, ginkgo biloba, and biotin | |
| EP1863434A2 (en) | A stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same | |
| JPH0665076A (en) | Antimycotic agent for external use | |
| WO2006084312A1 (en) | Method of promoting hair growth | |
| JP4438147B2 (en) | Powder aerosol formulation containing antifungal agent | |
| GB2164254A (en) | Stable topical compositions of anthralin | |
| WO1993017687A1 (en) | Topical compositions containing steroids | |
| JP2001181182A (en) | Antifungal liquid composition for external use | |
| JPH10167934A (en) | Hair growing agent | |
| JPH0567124B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20000508 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 9/12 A, 7A 61K 7/48 B, 7A 61K 7/00 B |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20010622 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20020917 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CONNETICS AUSTRALIA PTY LIMITED |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 17/00 20060101ALI20060614BHEP Ipc: A61Q 19/00 20060101ALI20060614BHEP Ipc: A61K 8/34 20060101ALI20060614BHEP Ipc: A61K 8/04 20060101ALI20060614BHEP Ipc: A61K 9/12 20060101AFI20060614BHEP |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REF | Corresponds to: |
Ref document number: 69836555 Country of ref document: DE Date of ref document: 20070111 Kind code of ref document: P |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20061228 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20070400455 Country of ref document: GR |
|
| ET | Fr: translation filed | ||
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2277394 Country of ref document: ES Kind code of ref document: T3 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20070926 Year of fee payment: 10 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH) |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20070830 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20071025 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20070910 Year of fee payment: 10 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: STIEFEL RESEARCH AUSTRALIA PTY LTD Free format text: CONNETICS AUSTRALIA PTY LIMITED#8 MACRO COURT#ROWVILLE VICTORIA 3178 (AU) -TRANSFER TO- STIEFEL RESEARCH AUSTRALIA PTY LTD#8 MACRO COURT#ROWVILLE, VICTORIA 3178 (AU) |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: PD4A Owner name: STIEFEL RESEARCH AUSTRALIA PTY LTD, AU Effective date: 20080618 |
|
| NLT1 | Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1 |
Owner name: STIEFEL RESEARCH AUSTRALIA PTY LTD. |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081031 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081019 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081019 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: STIEFEL RESEARCH AUSTRALIA PTY LIMITED Effective date: 20140212 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20170925 Year of fee payment: 20 Ref country code: FR Payment date: 20170922 Year of fee payment: 20 Ref country code: GR Payment date: 20170929 Year of fee payment: 20 Ref country code: FI Payment date: 20170925 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20170925 Year of fee payment: 20 Ref country code: IE Payment date: 20170925 Year of fee payment: 20 Ref country code: PT Payment date: 20170925 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20171027 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20171017 Year of fee payment: 20 Ref country code: IT Payment date: 20171016 Year of fee payment: 20 Ref country code: SE Payment date: 20171009 Year of fee payment: 20 Ref country code: ES Payment date: 20171107 Year of fee payment: 20 Ref country code: NL Payment date: 20171016 Year of fee payment: 20 Ref country code: AT Payment date: 20170925 Year of fee payment: 20 Ref country code: CH Payment date: 20171025 Year of fee payment: 20 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69836555 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20181018 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Effective date: 20181019 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20181018 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MK Effective date: 20181019 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 346588 Country of ref document: AT Kind code of ref document: T Effective date: 20181019 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20181026 Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20181019 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20181018 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20200724 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20181020 |